Tech Company Financing Transactions
Edgewood Oncology Funding Round
Alta Partners and private investors joined a $20 million Series A funding round for Edgewood Oncology. The financing round closed on 3/25/2024.
Transaction Overview
Company Name
Announced On
3/25/2024
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors
Alta Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance the clinical development of BTX-A51 in acute myeloid leukemia (AML) and a precision medicine approach to breast cancer.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
207 Washington Street P.O. Box 471012
Brookline, MA 02447
USA
Brookline, MA 02447
USA
Phone
Website
Email Address
Overview
Edgewood Oncology is a clinical-stage biotechnology company that was founded to deliver on the promise of BTX-A51 for patients with hematologic malignancies and genetically-defined solid tumors. Our mission is to develop an innovative medicine that improves and extends the lives of patients with the greatest unmet medical needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Cook
Chief Medical Officer
Zung Thai
Browse more venture capital transactions:
Prev: 3/25/2024: Q32 Bio venture capital transaction
Next: 3/25/2024: Finite State venture capital transaction
Share this article
Where The Data Comes From
We record all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs